Advertisement

Topics

Use of Genzyme's MS drug Lemtrada restricted under ongoing EMA safety review http://bit.ly/2Gi3KIt  #multiplesclerosis #pharmapic.twitter.com/AJzmEIk9pu

07:28 EDT 16 Apr 2019 | Pharmafile

Use of Genzyme's MS drug Lemtrada restricted under ongoing EMA safety review http://bit.ly/2Gi3KIt 

Original Article: Use of Genzyme's MS drug Lemtrada restricted under ongoing EMA safety review http://bit.ly/2Gi3KIt  #multiplesclerosis #pharmapic.twitter.com/AJzmEIk9pu

NEXT ARTICLE

More From BioPortfolio on "Use of Genzyme's MS drug Lemtrada restricted under ongoing EMA safety review http://bit.ly/2Gi3KIt  #multiplesclerosis #pharmapic.twitter.com/AJzmEIk9pu"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...